OMDA

AI Memo

Omada Health

As of 2026-09-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings and raised FY26 outlook • 2026-08-06

Base target: $28 / p=50% prob

Biggest risk

The CEO transition, unproven cholesterol and prescribing monetization, limited analyst-revision visibility, and recent founder selling create execution and expectation risks. The peer set is loose, so relative valuation evidence is weak.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

Q2 demonstrated strong operating momentum: 43% revenue growth, record 73% gross margin, positive net income, $11 million adjusted EBITDA, expanding PBM and employer distribution, and raised FY26 guidance [#SEC-8K-2026-08-06]. The Investor Day and 2027 product expansion could support further estimate revisions.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-04

Base target

$28

p=50%

Bull target

$35

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recent insider selling
Expansion of cardiometabolic and prescribing offerings
Q2 demonstrated strong operating momentum: 43% revenue growth, record 73% gross margin, positive net income, $11 million adjusted EBITDA, expanding PBM and employer distribution, and raised FY26 guidance [#SEC-8K-2026-08-06].

BearKey bullets

CEO transition could create execution or key-person risk despite the planned continuity.
Cholesterol management and prescribing initiatives have limited demonstrated revenue scale; the first prescribing customer is expected to contribute in 2027.
Direct peer and analyst-consensus coverage is limited, reducing confidence in relative valuation and target-price interpretation.

WatchKey bullets

Q2 2026 earnings and raised FY26 outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $28 (p=50%)

Target spread vs base: +24% / -38%

Scenario probabilities

Bull Target: $35 (p=25%)Base Target: $28 (p=50%)Bear Target: $18 (p=25%)

Commentary

News tone is constructive following strong Q2 results, raised guidance, and the announced Investor Day [#SEC-8K-2026-08-06]. Social, options, short-interest, employee-rating, and analyst-revision data are unavailable; missing data is not treated as positive evidence. Insider activity provides a modest counter-signal [#SEC-FORM4-2026-09-03].

As of 2026-09-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recent insider selling
Expansion of cardiometabolic and prescribing offerings

Scenarios

Bull Target (Scenario probability)

$35 / p=25% prob

Base Target (Scenario probability)

$28 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

78.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 earnings and raised FY26 outlook
Already reported: revenue grew 43% year over year to $88 million, gross margin reached 73%, adjusted EBITDA was $11 million, and FY26 revenue guidance was raised to $334-$340 million from $322-$330 million [#SEC-8K-2026-08-06].
Prob 100.00% • Move 10.00% • Priced-in 85.00%
EVENT2026-09-10
Investor Day on September 10, 2026
Omada plans to present its vision, strategy, and long-term growth plans. The event could clarify durability of growth, margin potential, and execution plans, but expectations may already reflect the strong Q2 print [#SEC-8K-2026-08-06].
Prob 80.00% • Move 8.00% • Priced-in 35.00%
EVENT2027-01-01
CEO transition effective January 1, 2027
President Wei-Li Shao is scheduled to become CEO while founder Sean Duffy becomes Executive Chair. Continuity appears planned, but the transition creates an execution and key-person monitoring point [#SEC-8K-2026-08-06].
Prob 90.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Recent insider selling
2026-09-30
Founder Sean Duffy reported open-market sales on September 1, while additional officer dispositions were reported for tax withholding. This is a secondary caution signal and does not establish operating weakness [#SEC-FORM4-2026-09-03].
Prob 50% • Move -4% • Priced-in 60%

Long-term Catalysts

Months to a year

Expansion of cardiometabolic and prescribing offerings
2027-12-31
The HCSC expansion reaches 1.5 million additional covered lives, cholesterol management has begun an initial deployment, and the first prescribing-program customer is expected to generate revenue in 2027. Conversion and scale remain unproven [#SEC-8K-2026-08-06].
Prob 60% • Move 15% • Priced-in 45%

Risks

CEO transition could create execution or key-person risk despite the planned continuity.
Cholesterol management and prescribing initiatives have limited demonstrated revenue scale; the first prescribing customer is expected to contribute in 2027.
Direct peer and analyst-consensus coverage is limited, reducing confidence in relative valuation and target-price interpretation.
Growth expectations may be elevated after the Q2 beat and raised outlook, increasing downside if enrollment, margins, or guidance decelerate.
Recent founder open-market sales and officer tax-related dispositions may weigh on sentiment, though they are not evidence of operating deterioration [#SEC-FORM4-2026-09-03].

Peers

Symbol	Summary
ATEC	Same-sector, similar-market-cap medtech reference, but orthopedic device exposure is not directly comparable to Omada's virtual cardiometabolic-care model.
CNMD	Same-sector, similar-market-cap medical-device reference; useful for broad operating context, not direct valuation comparison.
ENOV	Similar-market-cap healthcare-device reference with materially different products, reimbursement exposure, and growth drivers.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-04

Loading AI feed…

Symbol

Summary

ATEC

Same-sector, similar-market-cap medtech reference, but orthopedic device exposure is not directly comparable to Omada's virtual cardiometabolic-care model.

CNMD

Same-sector, similar-market-cap medical-device reference; useful for broad operating context, not direct valuation comparison.

ENOV

Similar-market-cap healthcare-device reference with materially different products, reimbursement exposure, and growth drivers.